Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy?
Clinical indications for immune checkpoint inhibitor (ICI) therapy are rapidly expanding for various stages of several solid tumors. The success of ICIs results from a complex interplay between cancer cells and their immune microenvironment. PD-1/PD-L1 PET imaging enables to study of these interactions in the tumor microenvironment in a clinical setting. These noninvasive, sensitive and quantitative tools may play an important role in optimizing ICI efficacy.
['Verhoeff|Sarah R|SR|', 'van den Heuvel|Michel M|MM|', 'van Herpen|Carla M L|CML|', 'Piet|Berber|B|', 'Aarntzen|Erik H J G|EHJG|', 'Heskamp|Sandra|S|']
D000074322:Antineoplastic Agents, Immunological D060890:B7-H1 Antigen D014408:Biomarkers, Tumor D002986:Clinical Trials as Topic D005544:Forecasting D006801:Humans D007167:Immunotherapy D009369:Neoplasms D000072078:Positron Emission Tomography Computed Tomography D049268:Positron-Emission Tomography D015899:Tomography, Emission-Computed, Single-Photon D059016:Tumor Microenvironment
Immunotherapy Checkpoint inhibitors Cancer PD-1 PD-L1 Molecular imaging immunoPET